Last updated: February 15, 2026
Overview
NDC 00173-0663 corresponds to Abaloparatide, marketed as Tymlos by Radius Health. Approved by the FDA in April 2017, it is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The drug is administered via daily subcutaneous injections. The primary competitors include Forteo (teriparatide) and other anti-osteoporotic agents.
Market Landscape
-
Postmenopausal osteoporosis affects roughly 20 million women in the U.S., with about 2 million classified as high-risk for fractures ([1]).
-
The global osteoporosis drug market was valued around $9 billion in 2021, projected to surpass $12 billion by 2027, growing at a CAGR of 5.2% ([2]).
-
Abaloparatide's targeted niche: high-risk women inadequately managed by bisphosphonates or other first-line treatments.
Prescription Trends
-
Initial uptake was slow, with about 5,000 prescriptions/month in 2018. Since then, market penetration increased, reaching approximately 15,000 prescriptions/month by 2022 ([3]).
-
Prescribed primarily in specialized osteoporosis clinics, with some adoption in general endocrinology practices.
-
Reimbursement policies influence access; private payers and Medicare have expanded formulary inclusion over time.
Pricing Data
-
List Price: Approximately $6,000 per 28-day supply (30 mcg/day dose), according to wholesale acquisition cost (WAC) ([4]).
-
Actual patient out-of-pocket cost varies with insurance, typically ranging from $50 to $150 per month after co-pays.
-
Bid and negotiated prices often reduce the effective price to approximately $4, None to $5,000 per month for payers.
Market Dynamics Impacting Price
-
Competition: Forteo (teriparatide) lists at around $4,200/month, serving as primary competitor ([5]).
-
Durability: Abaloparatide is approved for a maximum of two years’ treatment; ongoing use restrictions influence long-term revenue.
-
Reimbursement and Patents: The expiration of patents may open fixed-price biosimilar or generic options in the next 5–7 years, potentially reducing prices ([6]).
-
Off-Label Use: Limited for osteoporosis; mainly used within indicated populations.
| Price Projection Outlook (2023-2028) |
Year |
Estimated List Price (per 28-day supply) |
Notes |
| 2023 |
$6,000 |
Stable; no new competitors; high reformulation costs for biosimilars still affect entry. |
| 2024 |
$5,900–$6,100 |
Slight pressure from payers and competitive pricing strategies. |
| 2025 |
$5,800–$6,000 |
Biosimilar entrants likely; initial market penetration may lower average prices. |
| 2026 |
$5,600–$5,900 |
Increased biosimilar competition expected; aggressive pricing could reduce list price further. |
| 2027 |
$5,400–$5,800 |
Biosimilar market matures; price reductions accelerate. |
| 2028 |
$5,200–$5,600 |
Continued competition reduces pricing; market stabilizes. |
Factors Affecting Price Trajectory
- Biosimilar market entry, expected after patent expiry in 2024-2026.
- Pricing strategies adopted by Radius Health to maintain market share.
- Shifts in treatment guidelines favoring other agents.
- Reimbursement policies and payer negotiations.
Conclusion
Abaloparatide's market remains modest relative to broader osteoporosis therapeutics signaling a niche focus. While current prices are stable, the entry of biosimilars within next five years is projected to lower prices incrementally, with list prices potentially decreasing by approximately 10–15%. Payer pressure and competitive landscape will be primary drivers of downward price adjustments.
Key Takeaways
- NDC 00173-0663 (Abaloparatide) is valued at approximately $6,000 per month with limited off-label use.
- Competition from Forteo and upcoming biosimilars will likely push prices downward over the next five years.
- Market growth depends on approval expansion in other osteoporosis indications and geographic markets.
- Price sensitivity among payers will influence negotiated rates beyond list prices.
- Entry of biosimilars around 2024-2026 is the key factor for significant price reductions.
FAQs
-
What factors influence the pricing of Abaloparatide?
Pricing is affected by market competition, biosimilar entry, payer negotiations, and treatment guidelines.
-
When are biosimilars expected to enter the market?
Biosimilars are likely to enter the market between 2024 and 2026, following patent expiration.
-
How does the price compare with Forteo?
List prices are similar; Forteo’s approximate cost is $4,200/month, slightly lower than Abaloparatide.
-
What is the potential volume growth for Abaloparatide?
Prescription volume is projected to grow modestly with increased adoption among high-risk patients and expanded indications.
-
Are there any geographic markets with different pricing trends?
Yes; European markets and other emerging regions tend to have lower prices due to different reimbursement systems and competitive factors.
Sources
[1] National Osteoporosis Foundation. "Women and Osteoporosis." 2022.
[2] Research and Markets. "Global Osteoporosis Disease Market Forecast." 2021.
[3] IQVIA Prescriptions Data. 2022.
[4] Blue Book, First DataBank. Wholesale acquisition cost, 2023.
[5] Manufacturer’s Pricing Data. 2023.
[6] U.S. Patent and Trademark Office. Patent expiration estimates.
